Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

MM2: SARS-CoV-2 Antibody Response and the Role of Serology in COVID-19 Diagnosis and Epidemiology

In this presentation, Professor Sharon Lewin discusses the kinetics of the antibody response following SARS-CoV-2 infection, current tests for antibody detection, and the use of serology assays in COVID-19 diagnosis and epidemiological studies
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Released: May 28, 2020

Information on this Educational Activity

Faculty

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia

Sharon Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Program Medium

This program has been made available online.

Related Content

Expert commentary on updates in vaccine development for RSV, from Dr Angela Branche and Clinical Care Options (CCO)

person default Angela Branche, MD Released: April 7, 2022

Expert commentary on addressing barriers to vaccine uptake in older individuals, from Dr Barbara Resnick and Clinical Care Options (CCO)

Barbara Resnick, PhD, CRNP Released: January 12, 2022

Dr David E. Griffith describes the complex role of in vitro susceptibility testing in the management of NTM lung disease, from Clinical Care Options (CCO)

person default David E. Griffith, MD Released: December 1, 2021

Dr Princy N. Kumar describes the safety monitoring required of treatment for nontuberculous mycobacterial lung disease, from Clinical Care Options (CCO)

Princy N. Kumar, MD, FIDSA, MACP Released: November 30, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings